Drug Trial Radar · NCT07670884
A Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Tablets in Overweight or Obese Subjects
Last checked: Nov 19, 2026Latest source record: Aug 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
675
Planned (sponsor's estimate)
Start
Jul 24, 2026
Primary completion
Oct 31, 2027
Study completion Nov 30, 2027
Sponsor
- Lead sponsor
- Fujian Shengdi Pharmaceutical Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 26, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the efficacy and safety of HRS9531 tablets compared with placebo in reducing body weight in overweight or obese subjects after 52 weeks of treatment.
Conditions
- Chronic Management of Body Weight
Interventions
HRS9531 TabletDrug
HRS9531 tablet.
HRS9531 Tablet PlaceboDrug
HRS9531 tablet placebo.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage change from baseline in body weight after 52 weeks of treatmentTime frame: After 52 weeks of treatment.
- Proportion of subjects with weight loss of ≥ 5% from baseline in body weight after 52 weeks of treatmentTime frame: After 52 weeks of treatment.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Henan Provincial People's Hospital
Zhengzhou, Henan, China · Recruiting
Nanjing Drum Tower hospital
Nanjing, Jiangsu, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.